[WSJ] Will Gilead’s Hepatitis C Drug Bust State Budgets?

Will the cost of new hepatitis C treatments bust state budgets?

A new analysis suggests many states may, in fact, be overwhelmed as they attempt to pay for the Solvaldi medication sold by Gilead Sciences  GILD -0.41%, which costs $84,000 for each patient, and several forthcoming treatments that may be priced at a similar level.

[button title=”Read More” link=”http://blogs.wsj.com/pharmalot/2014/07/17/will-gileads-hepatitis-c-drug-bust-state-budgets/” target=”_blank” size=”” color=”” class=””]